American Capital goes up for sale

By Luisa Beltran — 1 month ago

American Capital Ltd. Said Friday that its board of directors has completed the initial phase of its strategic review. The board has authorized American Capital to proceed with its plan to solicit offers to buy the company or its various business lines in whole or in part. Goldman Sachs & Co. and Credit Suisse Securities are advising. American Capital announced in November that it was undertaking a full strategic review of alternatives.

Continue

Sunnova rakes in about $300 mln

By Iris Dorbian — 4 months ago

Residential solar service firm Sunnova Energy Corp has raised about $300 million in debt and equity funding. Triangle Peak Partners led the equity round with participation from other investors that included Franklin Square Capital Partners, which is advised by Blackstone‘s GSO Capital. Also, Credit Suisse arranged a conduit facility. In addition to the funding, Rob Horn from GSO Capital Partners, Mike Morgan and David Pesikoff from Triangle Peak Partners and C. Park Shaper from SEIS Holdings, have been added to Sunnova’s board of directors.

Continue

Humacyte snaps up $150 mln Series B, names Sebelius to board

By Iris Dorbian — 4 months ago

Humacyte, a biotech and regenerative medicine company, has secured $150 million in Series B funding. The investors included Access Industries, Bangkok Bank Public Company Ltd, Brady Dougan, Pacific Eagle Asset Management, Reignwood Group and Gavril Yushvaev. Credit Suisse was the placement agent. In conjunction with the funding, the company has named former U.S. Secretary of Health and Human Services Kathleen Sebelius and healthcare executive Dale A. Sander to its board of directors.

Continue

VC-backed Edge Therapeutics goes public

By Iris Dorbian — 4 months ago

Berkeley Heights, New Jersey-based Edge Therapeutics, a biotech company focused on developing therapies for neurological conditions, has debuted its IPO after pricing its over 7.3 million shares at $11 per share. The stock began trading Thursday on the NASDAQ under the ticker symbol “EDGE.” Leerink Partners and Credit Suisse are serving as the lead underwriters. Edge Therapeutics’ backers included Venrock, Sofinnova Ventures, Janus Capital Management LLC, New Leaf Venture Partners and BioMed Ventures.

Continue

Thoma Bravo to exit Sirius Computer Solutions

By Iris Dorbian — 5 months ago

Kelso & Company has agreed to acquire a stake in Sirius Computer Solutions Inc, an information technology solutions provider. The sellers are Thoma Bravo and Sirius founder Harvey Najim. No financial terms were disclosed. The transaction is expected to be completed in the fourth quarter of this year. Credit Suisse is providing financial advice to Kelso on the deal.

Continue

Waterland Private Equity exits SENIOcare

By Iris Dorbian — 6 months ago

Waterland Private Equity has sold its stake in Swiss nursing home operator SENIOcare to Swiss Prime Site AG. No financial terms were disclosed. Credit Suisse and Bär & Karrer provided advice to Waterland on the transaction.

Continue

Highstar Capital-backed Advanced Disposal files for IPO

By Iris Dorbian — 6 months ago

Advanced Disposal, a provider of solid waste collection, transfer, recycling and disposal services, has filed for an IPO. The number of shares the stock will sell as well as its pricing terms have yet to be set. Deutsche Bank Securities, Credit Suisse and Barclays are serving as the lead underwriters. Advanced Disposal is backed by Highstar Capital.

Continue

Nomad to buy Findus Group’s European frozen food business

By Iris Dorbian — 6 months ago

Nomad Foods has agreed to acquire Findus Group‘s European frozen food business for about 500 million pounds. The sellers, all of whom will receive 8.4 million shares of Nomad at the closing, include Highbridge Principal Strategies, Lion Capital LLP and Sankaty AdvisorsUBS Investment Bank and Credit Suisse provided financial advice to Nomad on the transaction.

Continue

VC-backed Aimmune Therapeutics goes public

By Iris Dorbian — 6 months ago

Brisbane, California-based Aimmune Therapeutics, a biopharmaceutical company focused on treating peanut allergies, has raised $160 million for its IPO after pricing its 10 million shares at $16 per share. The stock began trading Thursday on the NASDAQ under the ticker symbol “AIMT.” BofA Merrill Lynch, Credit Suisse and Piper Jaffray are serving as the lead underwriters. Aimmune’s backers include Longitude Capital, Foresite Capital and Aisling Capital.

Continue